



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN:L85100MH1973PLC289209

November 13, 2021

To,
Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400 001

Through: BSE Listing Centre
Scrip Code: 540788
Security ID: ASPIRA

Sub: Outcome of meeting of Board of Directors held on November 13, 2021

Dear Sirs,

In compliance with the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. on **Saturday, November 13, 2021** inter alia, has considered, approved and taken on record the following matter(s):

- i. Unaudited financial results of the Company for the quarter ended September 30, 2021. The unaudited financial results along with the Limited Review Report for the quarter ended September 30, 2021 are enclosed herewith.
- ii. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III of said Regulations, we would like to inform you that based on the recommendation of Nomination & Remuneration Committee, the Board of Directors of the Company at its meeting held on November 13, 2021, have approved appointment of Ms. Darshana Sawant as Company Secretary and Compliance Officer of the Company, in terms of provisions of Section 203 of the Companies Act, 2013 and Rules made thereunder and Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with effect from **November 15, 2021**.

The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is given in the enclosed Annexure.



**INDIA'S FIRST
FULLY INTEGRATED LAB**

☎ 022-7197 5756 🌐 www.aspiradiagnostics.com
✉ support@aspiradiagnostics.com | info@aspiradiagnostics.com

- iii. Investment through subscription of Compulsory Convertible Preference Shares ("CCPS") for aggregate amount not exceeding Rs. 1,00,00,000/- (Rupees One Crore Only), in or more offering(s) and/or tranches, subject to necessary approval including shareholder approval if required, as may be decided from time to time.

The above meeting of the Board of Directors commenced at 3:00^{N.M.} p.m and concluded at 4:55 p.m.

We request you to disseminate the above information on your website.

For Aspira Pathlab & Diagnostics Limited


Nikunj Mange
Executive Director
DIN: 08489442



Encl: As above

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Tel No. 022-71975756, Email : support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com

Unaudited Financial Results for the Quarter and Six months ended 30th September, 2021

(Rupees in Lakhs except as stated)

Particulars	Quarter ended			Six Months ended		Year ended
	30-Sep-21 (Unaudited)	30-Jun-21 (Unaudited)	30-Sep-20 (Unaudited)	30-Sep-21 (Unaudited)	30-Sep-20 (Unaudited)	31-Mar-21 (Audited)
1. Income						
(a) Revenue from Operations						
Sales/Income from Operations	349.06	588.39	537.56	937.44	689.79	1,520.54
(b) Other Income	2.34	2.21	6.73	4.55	13.57	20.38
Total Income	351.39	590.60	544.29	941.99	703.35	1,540.92
2. Expenses						
(a) Cost of Materials consumed	63.80	74.88	103.09	138.68	131.37	263.37
(b) Laboratory Testing Charges	24.19	69.39	75.95	93.58	82.41	206.34
(c) Employee benefits expense	121.70	114.57	95.34	236.28	180.89	402.57
(d) Finance Costs	6.85	7.09	24.58	13.94	48.29	89.15
(d) Depreciation and amortisation expense	38.25	37.76	35.44	76.00	71.85	144.45
(e) Other expenses	82.14	86.57	76.98	168.71	118.63	296.93
Total Expenses	336.93	390.26	411.39	727.19	633.44	1,402.82
3. Profit / (Loss) before exceptional items and tax (1-2)	14.46	200.34	132.90	214.80	69.91	138.10
4. Exceptional Items	-	-	-	-	-	-
5. Profit / (Loss) before tax (3+4)	14.46	200.34	132.90	214.80	69.91	138.10
6. Tax Expenses	-	-	-	-	-	-
7. Profit / (Loss) after tax (5-6)	14.46	200.34	132.90	214.80	69.91	138.10
8. Other Comprehensive income (net of tax)	-	-	-	-	-	13.27
9. Total Comprehensive income (7+8)	14.46	200.34	132.90	214.80	69.91	151.36
10. Paid up Equity share capital (face value of Rs.10 each)	1,029.30	1,029.30	929.30	1,029.30	929.30	1,029.30
11. Other Equity	-	-	-	-	-	(197.85)
12. Earning per share (in Rupees)						
(a) Basic	0.14	1.95	1.43	2.09	0.75	1.59
(b) Diluted	0.14	1.95	1.43	2.09	0.75	1.59

Notes

- The above unaudited financial results of the Company for the quarter and six months ended September 30, 2021 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 13th November, 2021.
- The above unaudited financial results for the quarter and six months ended September 30, 2021 has been subjected to limited review by statutory auditors of the Company. The auditors have expressed an unmodified opinion in the limited review report for the quarter and six months ended September 30, 2021. Also the figures for the quarter and six months ended September 30, 2021 were only reviewed and not subjected to audit.
- These unaudited financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.
- The Board of Directors of the Company, which has been identified as being the Chief operating decision maker, evaluates the Company's performance allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore, there is no reportable segment of the Company in accordance with requirement of Ind AS 108 - Operating Segment, notified under the Companies (Indian Accounting Standard) Rules, 2015.
- The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact after the Code becomes effective.
- The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED


 Dr. Pankaj J. Shah
 Managing Director
 DIN 02836324
 Place : Mumbai
 Date : 13.11.2021



ASPIRA PATHLAB & DIAGNOSTICS LIMITED
(CIN : L85100MH1973PLC289209)


Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086
Tel No. 022-71975756, Email :support@aspiradiagnostics.com,Website : www.aspiradiagnostics.com

Balance Sheet

(Rupees in Lakhs)

Particulars	As at 30 September 2021 (un-audited)	As at 31 March 2021 (Audited)
A ASSETS		
Non-current assets		
Property, plant and equipment	402.94	421.95
Right of Use Assets	122.06	73.57
Goodwill	265.18	265.18
Other Intangible assets	11.83	14.54
Financial Assests		
(i) Loans and advances	56.23	14.33
(ii) Others	171.20	-
Deferred tax assets (net)	-	-
Other Non-current assests	-	-
Total non-current assets	1,029.43	789.57
Current Assets		
Inventories	48.54	36.67
Financial Assests		
(i) Trade Receivables	237.73	170.27
(ii) Cash and Cash Equivalents	25.97	118.77
(iii) Bank balances other than (ii) above	-	-
(iv) Others financial assets	26.88	27.55
Current tax assets (net)	31.57	28.13
Other Current Assets	9.14	6.62
Total Current Assets	379.83	388.01
Total Assets	1,409.27	1,177.58
B EQUITY AND LIABILITIES		
EQUITY		
Equity share Capital	1,029.30	1,029.30
Other equity	16.95	(197.85)
Total Equity	1,046.25	831.45
LIABILITIES		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	81.27	76.67
(ii) Lease liabilities	98.63	48.55
(iii) Other Financial liabilities	-	-
Long term Provisions	25.88	19.78
Total non-current liabilities	205.78	145.00
Current liabilities		
Financial liabilities		
(i) Borrowings	-	48.39
(ii) Lease liabilities	28.72	34.83
(iii) Trade paybles	-	-
- Total outstanding dues of micro and small enterprises(MSME)	-	-
- Total outstanding dues of creditors other than MSME	69.44	66.49
(iv) Other financial liabilities	0.05	0.34
Other current liabilities	58.78	50.90
Short term Provisions	0.24	0.18
Total current liabilities	157.23	201.12
Total Liabilities	363.02	346.12
Total Equity and Liabilities	1,409.27	1,177.58

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED


Dr. Pankaj J. Shah
Managing Director
DIN. 02836324
Place : Mumbai
Date : 13.11.2021



ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086
Tel No. 022-71975756, Email :support@aspiradiagnostics.com,Website : www.aspiradiagnostics.com

Cash flow Statement for the half year ended 30th September 2021


(Rupees in Lakhs)

Particulars	For the period ended	For the period ended
	30.09.2021	30.09.2020
	(Un-Audited)	(Un-Audited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit/(Loss) for the year	214.80	69.91
Adjustments for:		
Interest income	(4.55)	(13.57)
Finance Costs	13.94	48.29
Depreciation and amortisation expenses	76.00	71.85
Provision for doubtful debts	8.64	1.96
CASH GENERATED BEFORE WORKING CAPITAL CHANGES	308.83	178.44
Adjustments for:		
(Increase)/Decrease in Trade receivables	(76.11)	(110.29)
(Increase)/Decrease in Inventories	(11.87)	(17.16)
(Increase)/Decrease in Current Security deposits	(1.26)	(13.50)
(Increase)/Decrease in Financial assets-Loans and advances	(41.90)	0.98
(Increase)/Decrease in other current assets	(2.52)	(2.22)
(Increase)/Decrease in Financial assets-others	(171.20)	-
(Increase)/Decrease in current tax assets(net)	(3.44)	-
Increase/(Decrease) in Trade payables	2.95	(7.84)
Increase/(Decrease) in short term Provisions	0.07	0.01
Increase/(Decrease) in Long term Provisions	6.10	4.72
Increase/(Decrease) in short term borrowings	(48.39)	-
Increase/(Decrease) in other Current Liabilities	7.88	(14.60)
Increase/(Decrease) in Other financial liabilities	(0.29)	(0.73)
CASH GENERATED FROM OPERATIONS	(31.14)	17.81
Taxes Paid (net of refunds)	-	-
NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)	(31.14)	17.81
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property , plant and equipment	(29.70)	(2.68)
Purchase of Intangible assets	(0.10)	(16.52)
Interest Received	4.55	13.57
NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)	(25.26)	(5.63)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long term borrowings	4.60	209.27
Repayment of long term borrowings	-	-
Repayment of Lease Liability	(27.06)	(23.15)
Interest paid	(13.94)	(48.29)
NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)	(36.40)	137.83
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(92.80)	150.00
Add:Cash and Cash Equivalents at the beginning of the year	118.77	9.65
Less: Cash Credits at the beginning of the year	-	(231.83)
Adjusted cash & cash equivalents at the beginning of the year	118.77	(222.17)
Cash and Cash Equivalents at the end of the year	25.97	(72.17)
Components of cash and cash equivalents comprise:		
Cash in hand	6.12	23.80
Balances with banks:		
-In Current Accounts	19.81	0.84
-In Escrow Account	0.04	0.35
-In Cash Credit Accounts	-	(97.16)
Cash and Cash Equivalents in cash flow statement	25.97	(72.17)

Note:

- 1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.
- 2) The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7 Statement of Cash Flows.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED


Dr. Pankaj J. Shah
Managing Director
DIN. 02836324
Place : Mumbai
Date : 13.11.2021





Independent Auditor’s Limited Review Report on the Quarterly and Six monthly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Aspira Pathlab & Diagnostics Limited**

We have reviewed the accompanying statement of **Unaudited Financial Results** of **Aspira Pathlab & Diagnostics Limited** (“the Company”) for the quarter and six months ended September 30, 2021 (“the Statement”) attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulation”) including relevant circulars issued by the SEBI from time to time.

The Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under section 133 of the Companies Act, 2013 (“the Act”) read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **P Khetan & Co**
Chartered Accountant
Firm Reg. No. 327386E



Rajesh D Sarfare
Partner

Membership No.- 140399
UDIN: 21140399AAAAAM5699

Place- Mumbai
Date- 13.11.2021

Annexure

Appointment of Ms. Darshana Sawant as Company Secretary and Compliance Officer of Aspira Pathlab & Diagnostics Limited

Sr. No	Particulars	Disclosure
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as Company Secretary and Compliance Officer
2	Date of appointment/cessation (as applicable) & term of appointment	Appointment w.e.f November 15, 2021 Appointed as Company Secretary and Compliance Officer of the Company by the Board of Directors at its meeting held on November 13, 2021, as per provision of Section 203 of the Companies Act, 2013 and terms of appointment as mentioned in appointment letter
3	Brief Profile	Ms. Darshana Sawant is a qualified member of Institute of Company Secretaries of India Membership No. A63226.
4	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Thanking you.

Yours Faithfully,

For Aspira Pathlab & Diagnostics Limited


Nikunj Mange
Executive Director
DIN: 08489442

